GlassScriptPhysician profile
Firas A Adeel
NPI 1679927842
$2,709.79
in general payments reported to CMS, 2019-2025
26 companies · $918 in 2025
The $918 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.32 · 2022: $448 · 2023: $701 · 2024: $551 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,168 · Education: $1.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,168.04 |
| Education | $1.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $409.60 | 2021-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $288.81 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $225.99 | 2021-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $190.90 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $174.29 | 2022-2025 | Jynarque |
| Horizon Therapeutics Plc | $165.00 | 2022-2023 | Krystexxa |
| Vifor Pharma, INC. | $152.17 | 2021-2025 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $151.00 | 2021-2025 | Velphoro |
| Mallinckrodt Hospital Products INC. | $132.33 | 2023-2025 | Terlivaz |
| Aurinia Pharma U.S., INC. | $118.51 | 2023-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $117.47 | 2022-2025 | Tarpeyo |
| Abbott Laboratories | $106.73 | 2023 | Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.06 | 2023-2025 | Jardiance |
| Travere Therapeutics, INC. | $84.30 | 2023-2025 | |
| Ardelyx, INC. | $47.29 | 2025 | Ibsrela |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $38.45 | 2023-2025 | Liberty Select Cycler, Nxstage System One, Pureflow Sl |
| Daiichi Sankyo INC. | $33.61 | 2022 | |
| Renalytix Ai, INC. | $24.75 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Apellis Pharmaceuticals, INC. | $23.50 | 2025 | |
| Cycle Pharmaceuticals INC | $22.00 | 2025 | Venxxiva |
| Kyowa Kirin, INC. | $19.32 | 2025 | |
| Lilly USA, LLC | $17.33 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $15.49 | 2022 | |
| Medtronic, INC. | $15.49 | 2024 | Symplicity G3 |
| Ani Pharmaceuticals, INC. | $15.34 | 2022 | |
| Opko Pharmaceuticals, LLC | $14.06 | 2023 | Rayaldee |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Firas Adeel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.